Pharmacovigilance Study to Evaluate Safety of SERETIDE in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
Primary objective: Evaluation of the safety of Seretide discus administration in subjects
with COPD. Treatment duration: 2 years. Study has 3 phases: Screening phase (visit 1),
treatment phase (visits 2-5. In the case of AE, there will be another visit (visit 6) as a
follow up visit - follow up phase.
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Salmeterol Xinafoate Xhance